$3.41
1.79% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US8106481059
Symbol
SCPH
Sector
Industry

scPharmaceuticals, Inc. Stock price

$3.41
-0.79 18.81% 1M
-0.10 2.85% 6M
-2.86 45.61% YTD
-2.09 38.00% 1Y
-1.37 28.66% 3Y
-1.43 29.55% 5Y
-10.69 75.82% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.06 1.79%
ISIN
US8106481059
Symbol
SCPH
Sector
Industry

Key metrics

Market capitalization $170.64m
Enterprise Value $131.66m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.35
P/S ratio (TTM) P/S ratio 5.64
P/B ratio (TTM) P/B ratio 5.56
Revenue growth (TTM) Revenue growth 303.87%
Revenue (TTM) Revenue $30.28m
EBIT (operating result TTM) EBIT $-63.69m
Free Cash Flow (TTM) Free Cash Flow $-70.56m
Cash position $91.48m
EPS (TTM) EPS $-1.91
P/E forward negative
P/S forward 4.67
EV/Sales forward 3.60
Short interest 9.33%
Show more

Is scPharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

scPharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a scPharmaceuticals, Inc. forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a scPharmaceuticals, Inc. forecast:

Buy
100%

Financial data from scPharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
30 30
304% 304%
100%
- Direct Costs 9.28 9.28
252% 252%
31%
21 21
333% 333%
69%
- Selling and Administrative Expenses 72 72
67% 67%
238%
- Research and Development Expense 12 12
14% 14%
41%
-63 -63
29% 29%
-210%
- Depreciation and Amortization 0.25 0.25
59% 59%
1%
EBIT (Operating Income) EBIT -64 -64
28% 28%
-210%
Net Profit -80 -80
59% 59%
-265%

In millions USD.

Don't miss a Thing! We will send you all news about scPharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

scPharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
13 days ago
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Nick Colangelo - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Anupam Leesy - Leerink Partners Stacy Ku - TD Cowen Douglas Tsao - H.C. Wainwrigh...
Neutral
GlobeNewsWire
13 days ago
Generated 3Q 2024 net FUROSCIX ® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million transformative financing in a combination of debt and equity that is anticipated to fund the Company throu...
Neutral
GlobeNewsWire
20 days ago
Management to host conference call and webcast, after-market on November 13, 2024, at 4:30 p.m. ET Management to host conference call and webcast, after-market on November 13, 2024, at 4:30 p.m. ET
More scPharmaceuticals, Inc. News

Company Profile

scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.

Head office United States
CEO John Tucker
Employees 136
Founded 2013
Website www.scpharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today